Comparison of thymic, lung, and pancreatic well‑differentiated high‑grade neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The LINEAR study will create a retrospective single‑center database of about 34 patients with advanced well‑differentiated high‑grade neuroendocrine tumors (Ki‑67 >20%) from thymus, lung, and duodeno‑pancreas. Clinical records, imaging, treatment sequences, outcomes, and available tumor tissue for molecular profiling will be collected and harmonized. The primary aim is to compare diagnostic pathways and therapeutic algorithms across the three primary sites to test whether management differs in practice. Secondary analyses will correlate genomic alterations with treatment activity and patient outcomes in a hypothesis‑generating translational framework.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist.
* Primary tumor site:thyme, lung and duodenum-pancreas NETs.
* Advanced stage of tumor disease and Any number of lines of therapy
* Sufficient available clinical data on diagnosis, treatments, outcomes.

Exclusion Criteria:

* Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 \< 20%.
* Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs)
* Inadequate or unavailable tumor tissue for molecular analysis.
* Incomplete clinical records or follow-up.
* Other primary sites, except lung or pancreas.

Where it's running

• European Institute of Oncology
  Milan, Italy, Italy Recruiting

Study contacts

• Principal investigator: Nicola Fazio, MD — Ieo
• Study coordinator: Cristiana Mulargiu, MD
• Email: divisione.gastrointestinale@ieo.it
• Phone: 00390257489258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Combining Durvalumab with Etoposide and Platinum for Lung Cancer Treatment

  This study is testing if combining a new immune therapy with chemotherapy can help people with advanced lung cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Centre Leon Berard · Aix-en-Provence and 30 other locations · NCT06393816

• DLL3-targeted alpha radiotherapy ([212Pb]Pb-MP0712) for advanced small cell lung cancer and DLL3-positive neuroendocrine tumors

  This will test a DLL3-targeted radioactive drug ([212Pb]Pb-MP0712) to see if it's safe and can shrink tumors in adults with advanced small cell lung cancer or other DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1/2 Molecular Partners AG · Tampa, Florida and 7 other locations · NCT07278479

• BL-M14D1 for people with advanced small cell lung cancer and other neuroendocrine tumors.

  This trial will try BL-M14D1 in adults with locally advanced or metastatic small cell lung cancer or other high-grade neuroendocrine tumors to see if it is safe and helps control the cancer after standard treatments have failed.

  Recruiting at 26 sites Phase 1 SystImmune Inc. · Huntsville, Alabama and 30 other locations · NCT07080242

• Neuroendocrine Carcinomas: Patient Paths and Outcomes in Latin America

  This is an observational study that will look at medical records to see how patients with neuroendocrine carcinomas in Latin America are diagnosed, treated, and how they fare.

  Recruiting at 4 sites Latin American Cooperative Oncology Group · Buenos Aires, Buenos Aires and 18 other locations · NCT07192991

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.